Raw Material Taxol Powder Extract Taxol Powder Taxol

• Customization: Available
• Certification: RoHS, BRC, ISO, FDA, HACCP
• Assay Method: HPLC-MS, GPC, HPLC, UV
• Model NO.: D-sung Taxol
• Application Form: Injection, Lotion, Suppository, Paste, Tablet, Capsule
• Application: Food, Health Care Products, Medicine
• State: Powder
• Extract Source: Taxol
• Shelf Life: 2 Years
• Density: 1.39 G/Cm³
• Flash Point: 532.6 ºC
• Mf: C47h51no14
• MW: 853.91
• Melting Point: 213 ºC
• Boiling Point: 957.1 ºC
• Einecs: 205-285-7
• Safety Instructions: S22
• Hazard Description: Xn
• Water Solubility: Insoluble in Water
• Number of Hydrogen Bond Donors: 4
• Number of Hydrogen Bond Acceptors: 14
• Number of Tautomers: 6
• Surface Charge: 0
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Raw Material Taxol powder Extract Taxol powder Taxol

Product Description

Product Details

Product Name	Taxol
CAS	33069-62-4
Appearance	White crystalline powder
MF	C47H51NO14
MW	853.92
Purity	99%
Shelf Life	2 Years

Taxol is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it 'taxol'. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to Taxol and the BMS compound is sold under the trademark 'Paclitaxel'. In this formulation, Taxol is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which Taxol is bound to albumin, is sold under the trademark Abraxane.

Application&Function

Function
1. Paclitaxe is a mitotic inhibitor drup used in the treatment of cancer.
2. Isolated the compound from the bark of the Pacific yew tree, Taxus brevifolia, and noted its antitumor activity in a broad range of rodent tumors.
3. Paclitaxe has since become an effective tool of doctors who treat patients with lung, ovarian, breast cancer, and advanced forms of Kaposi's sarcoma. 
 

Specification